Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy

Gynecologic and Obstetric Investigation

Volumn 58, Issue 1, 2004, Pages 19-21

  Watanabe, Takashi ^a   Minakami, Hisanori ^b   Sakata, Yoichi ^a   Matsubara, Shigeki ^a   Sato, Ikuo ^a   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Plasma TAFI activity; Plasma TAFI antigen; Plasma TAFI in pregnancy; TAFI after delivery

Indexed keywords

FIBRIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ADULT; ARTICLE; DELIVERY; FEMALE; FIBRINOLYSIS; GESTATIONAL AGE; HUMAN; PREGNANCY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; CARBOXYPEPTIDASE U; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; PROSPECTIVE STUDIES;

EID: 4344711704     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077178     Document Type: Article

References (14)

1. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
2. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-16608.
3. Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulator of the plasminogen system. J Clin Invest 1995;96:2534-2538.
4. Toglia MR, Weg JG: Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108-113.
5. Uszynski M: Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes. Eur J Obstet Gynecol Reprod Biol 1997;75:127-131.
6. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I: Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000;83:902-905.
7. Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P: TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001;115:150-152.
8. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN: Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80;829-835.
9. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H: Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001;104:1-6.
10. de Moerloose P, Mermillod N, Amiral J, Reber G: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: Comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. Thromb Haemost 1998;79:554-556.
11. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, Koschinsky ML: Acute phase mediators modulate thrombinactivatable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003;278:9250-9257.
12. Watts DH, Krohn MA, Wener MH, Eschenbach DA: C-reactive protein in normal pregnancy. Obstet Gynecol 1991;77:176-180.
13. Wright JG, Cooper B, Astedt B, Lecander I, Wilde JT, Preston FE, Greaves M: Fibrinolysis during normal human pregnancy: Complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988;69:253-258.
14. Watanabe T, Araki M, Mimuro J, Tamada T, Sakata Y: Fibrinolytic components in fetal membranes and amniotic fluid. Am J Obstet Gynecol 1993;168:1283-1289.